Feng Shiwei, Li Yan, Tan Zheng, Shen Shiyang
Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China.
Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China.
Int J Pharm. 2025 Mar 15;672:125295. doi: 10.1016/j.ijpharm.2025.125295. Epub 2025 Feb 4.
Nucleic acid drugs utilize DNA or RNA molecules to modulate abnormal gene expression or protein translation in cells, enabling precise treatment for specific conditions. In recent years, nucleic acid drugs have demonstrated tremendous potential in vaccine development and treating genetic disorders. Currently, the primary carriers for clinically approved nucleic acid therapies include lipid nanoparticles and viral vectors. Beyond that, metal-organic frameworks (MOFs) are highly ordered, porous nanomaterials formed through the self-assembly of metal ions and organic ligands via coordination bonds. Their porosity structure offers great loading efficiency, stability, tunability, and biocompatibility, making them an attractive option for nucleic acid delivery. Given the research on MOFs as nucleic acid carriers has garnered significant attention in recent years, this review provides an overview of the therapeutic strategies and advancements in MOF-mediated nucleic acid delivery. The unique properties of various MOF carriers are introduced, and different approaches for nucleic acid loading are parallelly compared. Moreover, a systematic classification based on the type of nucleic acid cargo loaded in MOFs and corresponding applications is thoroughly described. This summary outlines the unique mechanisms through MOFs enhance nucleic acid delivery and emphasizes their substantial impact on therapeutic efficacy. In addition, the utilization of MOF-mediated nucleic acid treatment in combination with other therapies against malignant tumors is discussed in particular. Finally, an outlook on the challenges and potential opportunities of this technology in future translational production and clinical implementation is presented and explored.
核酸药物利用DNA或RNA分子来调节细胞中的异常基因表达或蛋白质翻译,从而能够针对特定病症进行精准治疗。近年来,核酸药物在疫苗开发和治疗遗传疾病方面展现出了巨大潜力。目前,临床批准的核酸疗法的主要载体包括脂质纳米颗粒和病毒载体。除此之外,金属有机框架(MOF)是通过金属离子和有机配体通过配位键自组装形成的高度有序的多孔纳米材料。它们的孔隙结构具有很高的负载效率、稳定性、可调节性和生物相容性,使其成为核酸递送的一个有吸引力的选择。鉴于近年来对MOF作为核酸载体的研究已引起广泛关注,本文综述了MOF介导的核酸递送的治疗策略和进展。介绍了各种MOF载体的独特性质,并对核酸负载的不同方法进行了比较。此外,还详细描述了基于MOF中负载的核酸种类及其相应应用进行的系统分类。本综述概述了MOF增强核酸递送的独特机制,并强调了它们对治疗效果的重大影响。此外,还特别讨论了MOF介导的核酸治疗与其他治疗恶性肿瘤方法的联合应用。最后,对该技术在未来转化生产和临床应用中的挑战和潜在机遇进行了展望和探讨。